Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease

Christopher L. Gentile,1* Angela M. Nivala,1* Jon C. Gonzales,1 Kyle T. Pfaffenbach,1 Dong Wang,1 Yuren Wei,1 Hua Jiang,2 David J. Orlicky,3 Dennis R. Petersen,4 Michael J. Pagliassotti,1 and Kenneth N. Maclean2

1Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado; and Departments of Pediatrics, Pathology, and Pharmacy, University of Colorado School of Medicine, Aurora, Colorado

Submitted 13 October 2010; accepted in final form 20 September 2011

Taurine, 2-aminoethanesulfonic acid, is a major intracellular amino sulfonic acid with diverse physiological functions. Taurine supplementation may be beneficial in preventing various metabolic disturbances, including alcohol-induced liver damage. The present study was undertaken to evaluate the therapeutic potential of taurine to serve as a preventative treatment for diet-induced NAFLD. We report that taurine significantly mitigated palmitate-mediated caspase-3 activity, cell death, ER stress, and oxidative stress in H4IIE liver cells and primary hepatocytes. In rats fed a high-sucrose diet, dietary taurine supplementation significantly reduced hepatic lipid accumulation, liver injury, inflammation, plasma triglycerides, and insulin levels. The high-sucrose diet resulted in an induction of multiple components of the unfolded protein response in the liver consistent with ER stress, unfolded protein response induction, and hepatic lipid accumulation that was significantly ameliorated by dietary supplementation with taurine. Our results indicate that dietary supplementation with taurine offers significant potential as a preventative treatment for NAFLD.

oxidative stress; endoplasmic reticulum stress; inflammation; lipids; sucrose

* C. L. Gentile and A. M. Nivala contributed equally to this work.

Address for reprint requests and other correspondence: M. J. Pagliassotti, Dept. Of Food Science and Human Nutrition, 205 Gifford, Colorado State Univ., Fort Collins, CO 80523 (e-mail: pagliasm@cahs.colostate.edu).

NONALCOHOLIC FATTY LIVER disease (NAFLD) is a burgeoning metabolic disorder characterized by fatty infiltration of the liver (steatosis) with progression, in some people, to nonalcoholic steatohepatitis (NASH) and liver failure (35, 39). Presently, NAFLD is estimated to affect upwards of 24% of the general population, as well as 3–9% of all children in the United States (48, 78). Of great concern are statistics indicating that, within 10 years of diagnosis, nearly 20% of the patients presenting with NASH progress to cirrhosis (1, 8, 51). Recent data also suggest that NAFLD is independently associated with the development of cardiovascular disease and overall-obesity-related mortality (41, 59–61). Thus, in light of these data, there is a critical need to elucidate the mechanisms that mediate the development and progression of NAFLD and to identify potential therapies for the disease.

Although the pathogenesis of NAFLD remains uncertain, it has been suggested that various factors, including oxidative stress, proinflammatory cytokines, gut-derived bacterial endotoxin, and disruptions in lipid metabolism may contribute to the progression of the disease (20). Accumulation of lipids in nonadipose tissues can lead to cell dysfunction, such as insulin resistance and cell death, a phenomenon known as lipotoxicity (65). Experimental and clinical data indicate that excess fatty acids, in particular, long-chain saturated fatty acids, are an important determinant of liver cell integrity, liver function, and potentially, an independent risk factor for the progression from NAFLD to NASH (24, 64, 67).

An accumulating body of literature suggests that an important factor linking excess fatty acids to liver damage is dysfunction of the endoplasmic reticulum (ER). One factor linking sucrose and saturated fatty acids to liver damage is dysfunction of the endoplasmic reticulum (ER). Although there is currently no proven, effective therapy for NAFLD, the amino sulfonic acid taurine is protective against various metabolic disturbances, including alcohol-induced liver damage. The present study was undertaken to evaluate the therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.
hetero- and homozygous knockout of the taurine transporter develop chronic liver disease characterized by fibrosis, inflammation, and hepatocyte apoptosis (69). Interestingly, the beneficial effects of taurine are often accompanied by reductions in ER stress, suggesting a link between the therapeutic properties of taurine and restoration of ER homeostasis (36, 40, 80).

The present study was undertaken to examine the effects of taurine supplementation on cell and animal models of NAFLD with a view to assessing its potential as a preventative treatment. Our findings demonstrate that taurine mitigates palmitate-induced ER stress and cell death in primary hepatocytes and H4IIE liver cells. Taurine also significantly reduced lipid accumulation and liver damage in rats fed a high-sucrose diet and in mice injected with the ER stress-inducing compound tunicamycin. Collectively, our results indicate that part of the protective effects of taurine in diet-induced NAFLD are related to the amelioration of ER stress and that dietary supplementation with this compound offers significant potential as a preventative treatment for this disease.

**EXPERIMENTAL PROCEDURES**

**Experimental agents.** Fatty acids (Sigma, St. Louis, MO) were complexed to bovine serum albumin at a 2:1 molar ratio (72). Taurine and tunicamycin were purchased from Sigma.

**Cell culture.** The rat hepatoma liver cell line H4IIE (American Type Culture Collection, Manassas, VA) was cultured in DMEM containing 8 mM glucose and supplemented with 10% fetal bovine serum, penicillin, and streptomycin sulfate. Experiments were performed at 80–100% cell confluence. In preparation for primary cell culture, hepatocytes were isolated from male, Wistar rats (Charles River, Wilmington, MA) by collagenase perfusion (2, 68). All procedures involving rats were reviewed and approved by the Colorado State University Institutional Animal Care Committee. Cells were first incubated in Roswell Park Memorial Institute media (RPMI; HyClone, Logan, UT) containing 11 mM glucose, 10^{-7} M dexamethasone, and 10^{-8} M insulin. The following morning, experimental treatments were performed using RPMI that contained 8 mM glucose and 10^{-7} M dexamethasone (control low-glucose medium). Each independent experiment was performed in triplicate, and taurine, when present, was 1% wt/vol.

**Animals.** Male Wistar Crl(WI)BR rats (Charles River, Wilmington, MA) weighing ~180 g (7–8 wk of age) on arrival were provided free access to a purified high-starch diet (68% of energy from corn starch, 12% from corn oil, and 20% from casein; Research Diets, New Brunswick, NJ) (46) and water for 1 wk. Rats were housed individually in a temperature- and humidity-controlled environment with a 12:12-h light-dark cycle. All procedures were reviewed and approved by the Colorado State University institutional animal care committee. After the 1-wk acclimation period, rats were fed either the high-starch diet (STD) or a high-sucrose diet (HSD; 68% of energy from sucrose, 12% from corn oil, 20% from casein; Research Diets) (46) for 4 wk. Dietary groups were randomly assigned to either normal drinking water (n = 6 per diet) or to drinking water that contained taurine (2% wt/vol; n = 6 per diet). Water and food intake were measured every other day, and body weight was measured weekly. To evaluate the effects of both diet and taurine on ER stress in hepatocytes, freshly isolated hepatocytes were taken from a separate group of rats (n = 4 per diet per treatment).

Male, C57BL/6J mice (7–11 wks) were housed in colony cages and maintained on a 12:12-h light-dark cycle. Mice were randomly assigned to one of four treatment groups (n = 6 for each group): 1) control, intraperitoneally injected with PBS; 2) taurine, mice were provided taurine (2% wt/vol added to the drinking water) for 1 wk prior to sham injection with PBS; 3) tunicamycin, intraperitoneally injected with tunicamycin; and 4) tunicamycin + taurine, mice were provided taurine (2% wt/vol added to the drinking water) for 1 wk prior to intraperitoneal injection with tunicamycin. Previous work has shown that the dose of tunicamycin used (0.5 mg/kg body wt) results in lassitude, lack of grooming, weight loss, liver injury, and hepatic steatosis that peaks between days 4 and 5 postinjection (79). In the taurine and tunicamycin + taurine groups, taurine treatment was maintained until death at 4 days after vehicle/tunicamycin injection.

![Fig. 1. Fatty acid-mediated cell death in H4IIE liver cells and primary hepatocytes. Caspase-3 activity (A); ELISA-based cell death in H4IIE liver cells (B, left) and primary hepatocytes (B, right). Cells were incubated for 16 h in control media (low-glucose medium (LG)) or LG supplemented with albumin-bound oleate at 250 μM (O250) or 500 μM (O500), palmitate at 250 μM (P250), or 500 μM (P500) in the absence (no additions) or presence of taurine (1% wt/vol). Values are means ± SD for n = 6–8 independent experiments. *Significantly different from same condition without taurine.](http://ajpregu.physiology.org/10.22022.32.246)
Four days postinjection, all mice were anaesthetized (isoflurane/oxygen) and killed by decapitation, and blood samples were collected for plasma analysis. Livers were removed and weighed, and samples were then either immersion fixed overnight in 4% paraformaldehyde in PBS (pH 7.3) for subsequent histological analysis or were snap frozen in liquid nitrogen. The animal care and procedures were approved by the Animal Care and Use Committee of the University of Colorado at Denver Health Sciences Center and the Guide for the Care and use of Laboratory Animals prepared by the National Academy of Sciences.

RNA isolation and analysis. Total RNA was extracted with Trizol reagent using the manufacturer’s protocol (Invitrogen, Carlsbad, CA). For analysis of XBP1 splicing, a two-step protocol was used for reverse transcription polymerase chain reaction (PCR) using SuperScript II reverse transcriptase and Taq polymerase (68). For real-time PCR, reverse transcription was performed using 0.5 μg of DNase-treated RNA, SuperScript II RnaseH−, and random hexamers. PCR reactions were performed in 96-well plates using transcribed cDNA and IQ-SYBR green master mix (Bio-Rad, Hercules, CA). Primer sets can be found in a previous publication (72). PCR efficiency was between 90 and 105% for all primer and probe sets and linear over five orders of magnitude. The specificity of products generated for each set of primers was examined for each fragment using a melting curve and gel electrophoresis. Reactions were run in triplicate, and data was calculated as the change in cycle threshold (ΔCT) for the target gene relative to the ΔCT for β2-microglobulin and cyclophilin (control genes), according to the procedures of Muller et al. (38). Results were similar regardless of the control gene; therefore data in RESULTS are reported using β2-microglobulin.

Immunoblot analysis. Cells and liver tissue were processed as described previously (67). Equivalent amounts of protein (50 μg) were subjected to SDS-PAGE, transferred to Hybond-P membranes (Amersham Pharmacia Biotech, Piscataway, NJ), and the membranes were incubated with antibodies against glucose regulated protein 78 (GRP78; Stressgen, Ann Arbor, MI), phospho-eukaryotic initiation factor 2-α (p-eIF2α; Cell Signaling, Waverly, MA), eIF2α (Cell Signaling), TNF-α (Cell Signaling), phospho-IKKα/β (IKKβ; Cell Signaling), C/EBP homologous protein (CHOP; Santa Cruz Biotechnology, Santa Cruz, CA), activating transcription factor-4 (ATF4; Santa Cruz Biotechnology), protein kinase-like ER kinase (PERK; Santa Cruz Biotechnology), phospho-PERK (Santa Cruz Biotechnology), and/or β-actin (Sigma). Proteins were detected using horseradish peroxidase-conjugated secondary antibodies and an enhanced chemiluminescence reagent (Pierce, Rockford, IL). Density was quantified using a UVP Bioimaging system (Upland, CA).

Determination of caspase activity and cell death. Activity of the caspase-3 class of cysteine proteases was determined with the Colorimetric Caspase-3 Activation Assay, which uses a caspase-specific peptide that is conjugated to the color reporter molecule p-nitroanaline (R&D Systems, Minneapolis, MN). Caspase activity was normalized to cell lysate protein concentration. Cell death was examined using the Cell Death Detection ELISA kit (Roche Diagnostics, Penzberg, Germany). The assay is based on the quantitative sandwich-enzyme immunoassay-principle using mouse monoclonal antibodies directed against DNA and histones. This allows specific determination of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates.

Fig. 2. Fatty acid-mediated endoplasmic reticulum (ER) stress in H4IIE liver cells. C/EBP homologous protein (CHOP) and growth arrest and DNA damage-inducible protein 34 (GADD34) mRNA (A); unspliced (u) and spliced (s) X-box-binding protein-1 (Xbp1) mRNA (B); and GRP78, phosphorylated eIF2α (p-eIF2α), total eIF2α, and actin protein (C). Incubations were exactly as described in Fig. 1 with the exception that the duration of the incubations was 6 h. In graphs, values are means ± SD for n = 6–8 independent experiments, and gels are representative of n = 6–8. Note the different order of treatments between blot and graph for eIF2α. *Significantly different from same condition without taurine (1% wt/vol).
**2,7-Dichlorofluorescein fluorescence and protein carbonyl formation.** Oxidative stress was estimated using 2,7-dichlorofluorescein di-acetate (DCFH-DA) (14). This assay is based on the ability of DCFH-DA to diffuse across the cell membrane and, following enzymatic hydrolysis to DCFH, oxidized to the fluorescent compound 2',7'-dichlorodihydrofluorescein (DCF). Following treatments, cells were loaded with 5 μM DCFH-DA (Molecular Probes), using serum-free media, for 45 min at 37°C (17). Fluorescence was monitored with excitation and emission wavelengths of 490 and 535 nm, respectively. Data are reported as the fold increase in median fluorescence over control cells. Protein carbonyls were measured using an ELISA-based kit (Biocell, New Zealand). Briefly, protein samples were reacted with dinitrophenylhydrazine at room temperature for 45 min, after which time samples were rinsed, and a blocking solution was added for 1 h. Antidinitrophenylhydrazine antibody and, subsequently, a secondary antibody, were both added for 1 h. Finally, substrate buffer was added for 10 min, and absorbance was measured at 405 nm.

**Histology.** Paraffin-embedded sections were stained with either hematoxylin and eosin or Masson trichrome. Histological examination was performed in a blinded fashion using the procedures described by Brunt et al. (4) as modified by Kleiner et al. (25). Images were captured on an Olympus BX51 microscope equipped with a four-megapixel Macrofire digital camera (Optronics; Goleta, CA) using the PictureFrame Application 2.3 (Optronics).

**Immunohistochemistry.** Paraffin-embedded liver samples were cut as 4-μm-thick serial sections. The unfolded protein response (UPR) was analyzed using an anti-KDEL (a tetrapeptide located at the COOH-terminal sequence of luminal proteins) monoclonal antibody (SPA-827), which recognizes both glucose-regulated protein (GRP)78/Bip and GRP94 (StressGen Biotechnologies Ann Arbor, MI). The anti-CHOP polyclonal Ab (sc-575) was purchased from Santa Cruz Biotechnology. Anti-KDEL was diluted 1:50 and used without antigen retrieval. Rabbit anti-CHOP polyclonal antibody was diluted 1:40 and applied after heat retrieval in Retrieve-all 2 (Signet Laboratories) at 95°C for 30 min and a 10-min incubation in 0.1% Triton-X. Sections were deparaffinized, and the endogenous peroxidase activity was blocked with 0.5% H2O2 in methanol for 10 min. After blocking with 5% normal goat serum, sections were incubated with primary antibody for 1 h at room temperature followed by goat anti-rabbit or rabbit anti-mouse biotinylated secondary antibodies (Vector Laboratories); diluted 1:500 in 0.05 mol/l Tris buffer, pH 7.5, for 30 min, and streptavidin-peroxidase (Zymed Laboratories); and diluted 1:20, for 5 min. Sections were developed in Nova Red peroxidase substrate (Vector Laboratories) and counterstained with hematoxylin. Nonspecific immunostaining was not detected in sections stained with nonimmune IgG as the primary antibody or with the secondary antibody alone.

**Hepatic and hepatocyte lipids.** Liver lipid was extracted using the procedure of Bligh and Dyer (3). Triglyceride concentration was determined using a kit (Sigma).

**Plasma measures.** Glucose was measured with an automated analyzer (Beckman Instruments, Fullerton, CA). Insulin and C-reactive protein were analyzed by ELISA (Linco Research, St. Charles, MO and Helica, Fullerton, CA, respectively). Plasma TNF-α levels were determined by ELISA (R&D systems). To assess the level of systemic oxidative stress, plasma levels of reactive aldehydes formed by lipid peroxidation were determined using a thiobarbituric acid reactive substances (TBARS) assay. TBARS determinations were carried out with an OXI-TEK TBARS Assay Kit (Alexis Biochemicals, San Diego, CA), according to the manufacturer's standard protocol with

![Fig. 3. Fatty acid-mediated ER stress in primary hepatocytes. CHOP and GADD34 mRNA (A); unspliced (u) and spliced (s) Xbp1 mRNA (B); and GRP78, p-eIF2α, total eIF2α, and actin protein (C). Incubations were exactly as described in Fig. 1 with the exception that the duration of the incubations was 6 h. Values in graphs are means ± SD for $n = 6$ independent experiments, and gels are representative of $n = 6$. Note the different order of treatments between blot and graph for GRP78 and eIF2α. *Significantly different from same condition without taurine (1% wt/vol).](http://ajpregu.physiology.org/doi/abs/10.1152/ajpregu.00297.2011)
Effects of taurine on palmitate-mediated cell death in liver cells. We have previously reported that saturated fatty acids, but not unsaturated fatty acids, cause liver cell death (71, 72). Palmitate-mediated cell death appears to be caspase dependent and is consistently present after 16-h but not 6-h incubations (71, 72). In the present study, we first examined the effects of taurine on palmitate-mediated caspase-3 activity and cell death. The unsaturated fatty acid oleate was used as a negative control. Taurine reduced (71, 72). In the present study, we first examined the effects of taurine on palmitate-mediated caspase-3 activity and liver cell death. The unsaturated fatty acid oleate was used as a negative control. Taurine reduced (71, 72). In the present study, we first examined the effects of taurine on palmitate-mediated caspase-3 activity and cell death.

**RESULTS**

Effects of taurine on palmitate-mediated cell death in liver cells. We have previously reported that saturated fatty acids, but not unsaturated fatty acids, cause liver cell death (71, 72). Palmitate-mediated cell death appears to be caspase dependent and is consistently present after 16-h but not 6-h incubations (71, 72). In the present study, we first examined the effects of taurine on palmitate-mediated caspase-3 activity and liver cell death. The unsaturated fatty acid oleate was used as a negative control. Taurine reduced (P < 0.05) but did not normalize triglyceride accumulation in response to both palmitate and oleate (data not shown). Taurine significantly reduced palmitate-mediated induction of caspase-3 activity and cell death in H4IIE liver cells and primary hepatocytes following 16-h incubations at palmitate concentrations of 500 μM, but not at 250 μM (Fig. 1). Taurine did not significantly affect the cellular utilization of glucose or free fatty acids based on the net loss of these nutrients from the medium (data not shown).

**Effects of taurine on palmitate-mediated ER stress in liver cells.** Disruption of ER homeostasis, collectively termed ER stress, activates the UPR (23). The UPR is initiated by three ER transmembrane proteins, inositol requiring ER-to-nucleus signaling protein-1α (IRE1α), RNA-dependent protein kinase-like ER eukaryotic initiation factor-2α kinase (PERK), and activating transcription factor-6 (ATF6) (53). Activation of IRE1α promotes the splicing of X-box-binding protein-1 (Xbp1) mRNA and subsequent transcription of molecular chaperones (e.g., GRP78) and genes involved in ER-associated degradation (57). PERK activation leads to phosphorylation of the α-subunit of the translation initiation factor eIF2 and subsequent attenuation of translation initiation, as well as increased expression of GRP78, CHOP, a proapoptotic gene, and growth arrest and DNA damage-inducible protein 34 (GADD34) (22, 57). GADD34 mediates dephosphorylation of eIF2α and therefore reversal of translational attenuation (53). Activation of ATF6 can also lead to increased expression of both molecular chaperones and CHOP. Taurine reduced, but did not prevent, the palmitate-mediated increase in CHOP and

![Graph](http://ajpregu.physiology.org/Download/10.1152/ajpregu.00010.2017)

**Table 1. General and metabolic characteristics**

<table>
<thead>
<tr>
<th>Variable</th>
<th>STD</th>
<th>STD+T</th>
<th>HSD</th>
<th>HSD+T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily food intake, kcal</td>
<td>93.5 ± 4.4</td>
<td>99.9 ± 10.4</td>
<td>100.0 ± 10.0</td>
<td>105.1 ± 5.7</td>
</tr>
<tr>
<td>Daily taurine intake, g</td>
<td>0.8 ± 0.1</td>
<td>0.8 ± 0.1</td>
<td>0.8 ± 0.1</td>
<td>0.9 ± 0.2</td>
</tr>
<tr>
<td>Weight gain, g</td>
<td>166.8 ± 15.3</td>
<td>191.7 ± 29.1</td>
<td>185.2 ± 22.5</td>
<td>188.8 ± 16.9</td>
</tr>
<tr>
<td>Epidydymal fat, g</td>
<td>7.2 ± 1.4</td>
<td>8.5 ± 1.9</td>
<td>9.9 ± 2.2</td>
<td>7.4 ± 0.9</td>
</tr>
<tr>
<td>Retroperitoneal fat, g</td>
<td>6.1 ± 3.0</td>
<td>8.2 ± 3.7</td>
<td>8.0 ± 2.4</td>
<td>6.2 ± 0.9</td>
</tr>
<tr>
<td>Plasma glucose, mg/dl</td>
<td>139.0 ± 6.0</td>
<td>145.0 ± 4.0</td>
<td>153.0 ± 6.0</td>
<td>149.0 ± 6.0</td>
</tr>
<tr>
<td>Plasma insulin, ng/ml</td>
<td>0.9 ± 0.2</td>
<td>1.0 ± 0.2</td>
<td>2.0 ± 0.3</td>
<td>1.5 ± 0.1</td>
</tr>
<tr>
<td>Plasma FFA, mM</td>
<td>0.30 ± 0.04</td>
<td>0.32 ± 0.03</td>
<td>0.33 ± 0.04</td>
<td>0.37 ± 0.03</td>
</tr>
<tr>
<td>Plasma TG, mM</td>
<td>0.39 ± 0.09</td>
<td>0.48 ± 0.09</td>
<td>1.10 ± 0.08</td>
<td>0.55 ± 0.10</td>
</tr>
<tr>
<td>Liver TG, μmol/g</td>
<td>6.4 ± 0.7</td>
<td>7.1 ± 0.6</td>
<td>12.1 ± 0.6</td>
<td>10.2 ± 0.5</td>
</tr>
</tbody>
</table>

Values are means ± SD. STD, high-starch diet; STD+T, STD+taurine; HSD, high-sucrose diet; HSD+T, HSD+taurine; FFA, free fatty acids; TG, triglycerides. *Taurine intake estimated based on daily water consumption. †Significantly different from all other groups. ‡Significantly different from STD and STD+T; §significantly different from HSD.
GADD34 mRNA, GRP78 protein, and phosphorylation of eIF2α in H4IIE liver cells (Fig. 2) and primary hepatocytes (Fig. 3). Taurine had little or no effect on palmitate-mediated Xbp1 splicing in either cell type (Figs. 2 and 3).

**Effects of taurine on palmitate-mediated oxidative stress.** Reduced oxidative stress has been identified as a potential mechanism by which taurine exerts its protective effects. The antioxidant properties of taurine include the ability to scavenge reactive oxygen species and reduce lipid peroxidation (11, 49). Thus, we next examined the effects of taurine on palmitate-mediated oxidative stress. Palmitate, but not oleate, increased (P < 0.05) DCF fluorescence in both H4IIE liver cells and primary hepatocytes, and these effects were prevented by coinubation with taurine (Fig. 4A). Time course studies re-

---

**Fig. 5. Effects of taurine on hepatic steatosis and liver histology in rats provided a high-starch (STD) or high-sucrose diet (HSD). Hematoxylin and eosin (H&E) staining and analysis of steatosis score (A) and H&E and trichrome staining (B). Liver sections from animals in each of the dietary groups was stained with either H&E or Masson trichrome and examined histologically. STD, for 4 wks; STD + T, STD and drinking water with 2% (wt/vol) taurine for 4 wks; HSD, for 4 wk; HSD + T, HSD for 4 wk and drinking water with 2% taurine (wt/vol). In the graph, dietary groups are compared using a point score: 0 = < 10% of hepatocytes exhibiting steatosis; 1 = 10–33% exhibiting steatosis; 2 = 34–66% exhibiting steatosis; 3 = > 66% exhibiting steatosis. B: representative, equal-sized periportal areas are shown (small arrows). Periportal region from sucrose-fed rat appeared thickened and more uniformly red, indicative of hyalinization. Large arrows in the H&E stain from sucrose-fed rat show the hepatic artery, in which no hyalinization was present. Scale bar = 100 microns. Values in graph are means ± SD for n = 6 per group. *Significantly different from other dietary groups.**
revealed that the palmitate-mediated increase in DCF fluorescence was observed after 2 h and was maximal after 6 h (data not shown). Dose-response studies demonstrated that 0.25 and 0.5% taurine did not effectively reduce DCF fluorescence (data not shown). Additionally, palmitate, but not oleate, increased protein carbonyls, and the presence of taurine significantly reduced this effect in both cell types (Fig. 4B).

Effects of taurine on high-sucrose diet-induced hepatic steatosis, ER stress, inflammation, and liver injury. To date, the role of dietary fat and blood lipids in obesity and NAFLD/NASH have probably attracted the majority of attention. However, previous work in our laboratory has shown that a high-sucrose diet induces hepatic steatosis characterized by increased saturated fatty acids, ER stress, liver injury, and insulin resistance in rats (45, 63, 67). To further investigate the therapeutic potential of taurine, we examined the effects of taurine supplementation in a rat model of high-sucrose, diet-induced NAFLD. The high-sucrose diet significantly increased plasma insulin, plasma triglycerides, and liver triglycerides (Table 1, Fig. 5A). Histological analysis also demonstrated that lipid was present in a larger percentage of hepatocytes in sucrose-fed rats compared with all other groups (Fig. 5A). Taurine supplementation effectively reduced sucrose-mediated increases in insulin, triglycerides, and hepatic steatosis (Table 1 and Fig. 5A). Hyalinization of the portal vein wall was also present in sucrose-fed rats but not in the other groups (Fig. 5B). None of the dietary groups were characterized by the presence of ballooned cells, acidophil cells, pigmented macrophages, or glycogenated nuclei. Sucrose-fed rats were also characterized by hepatic ER stress (Fig. 6), increases in or activation of inflammatory pathway proteins (Fig. 7A), liver injury (Fig. 7B), increases in markers of systemic inflammation (Fig. 7C), and systemic oxidative stress (Fig. 7C), all of which were reduced by taurine supplementation. To examine whether hepatocytes were also characterized by changes in ER stress markers we examined freshly isolated hepatocytes. Hepatocytes isolated from sucrose-fed rats were characterized by an increase in ER stress markers, all of which were reduced by taurine supplementation (Table 2).

Effects of taurine on high-sucrose diet-induced hepatic gene expression. To examine potential molecular mechanisms for taurine-mediated changes in hepatic steatosis we examined...
gene expression profiles for several lipogenic and oxidative genes. The high-sucrose diet increased fatty acid synthase (Fasn), acetyl-CoA carboxylase 1 (Acc1), stearoyl-CoA desaturase (Scd1) and PPAR-γ coactivator 1-α (Pgc1a) mRNA levels (Fig. 8). Taurine supplementation reduced sucrose-mediated induction of Fasn and Acc1 gene expression (Fig. 8).

Effects of taurine on tunicamycin-induced hepatic steatosis, liver injury, and UPR induction. The experiments described above indicate that taurine may be exerting its protective effects in diet-induced NAFLD by ameliorating oxidative stress, inflammation, and ER stress. A major complication to our understanding of the protective mechanisms of taurine supplementation is the fact that these pathogenic features are interrelated phenomena with each capable of inducing the other (32, 33). In an effort to dissect the protective mechanisms of taurine in NAFLD, we used an animal model of tunicamycin-induced steatosis and liver injury as described in MATERIALS AND METHODS. Tunicamycin injection resulted in hepatic steatosis and concomitant increases in liver weight, plasma alanine aminotransferase, (ALT) and aspartate aminotransferase (AST) (C). Tunicamycin injection resulted in hepatic steatosis and concomitant increases in liver weight, plasma alanine aminotransferase, (ALT) and aspartate aminotransferase (AST) (C). Values are means ± SD for n = 4–6 per group and Western blots are representative. *Significantly different from other dietary groups.

Table 2. Endoplasmic reticulum stress markers in hepatocytes isolated from rats fed an STD or HSD

<table>
<thead>
<tr>
<th>Variable</th>
<th>STD</th>
<th>STD+T</th>
<th>HSD</th>
<th>HSD+T</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-PERK/Actin</td>
<td>0.77 ± 0.19</td>
<td>0.84 ± 0.17</td>
<td>1.84 ± 0.32*</td>
<td>0.92 ± 0.21</td>
</tr>
<tr>
<td>eIF2α/eIF2α</td>
<td>1.1 ± 0.24</td>
<td>1.0 ± 0.21</td>
<td>2.05 ± 0.36*</td>
<td>1.23 ± 0.20</td>
</tr>
<tr>
<td>ATF4/Actin</td>
<td>1.41 ± 0.34</td>
<td>1.29 ± 0.30</td>
<td>2.45 ± 0.37*</td>
<td>1.37 ± 0.29</td>
</tr>
<tr>
<td>GRP78/Actin</td>
<td>0.79 ± 0.16</td>
<td>0.71 ± 0.17</td>
<td>1.35 ± 0.27*</td>
<td>0.89 ± 0.19</td>
</tr>
<tr>
<td>CHOP/Actin</td>
<td>0.23 ± 0.05</td>
<td>0.20 ± 0.06</td>
<td>0.97 ± 0.11*</td>
<td>0.31 ± 0.07</td>
</tr>
</tbody>
</table>

Values are arbitrary optical density units and are reported as means ± SD. PERK, protein kinase-like ERK; eIF2α, phospho-eukaryotic initiation factor-2α; eIF2α, eukaryotic initiation factor-2α; ATF4, activating transcription factor-4; GRP78, glucose regulated protein-78; CHOP, C/EBP homologous protein. *Significantly different from all other groups.

Fig. 8. Effects of taurine on hepatic gene expression in rats provided STD or HSD. Srebp1, sterol regulatory element binding protein-1; Fasn, fatty acid synthase; Acc1 and -2, acetyl CoA carboxylase 1 and 2; Chrebp, carbohydrate response element binding protein; Scd1, stearoyl-CoA desaturase-1; Cpt1a, carnitine palmitoyl transferase 1a; Pgc1a, peroxisome proliferator-activated receptor-γ coactivator 1; Ppara, peroxisome proliferator-activated receptor-α mRNA. Groups are described in Fig. 5. Values are means ± SD for n = 6 per group. *Significantly different from other dietary groups.
not transferase, and liver lipid content (Fig. 9). Hepatic lipid accumulation and liver injury were significantly attenuated by taurine supplementation (Fig. 9). The effect of taurine upon tunicamycin mediated induction of the UPR was analyzed by immunohistochemistry. This analysis revealed that taurine supplementation reduced the induction of proteins containing the KDEL signal sequence and completely ablated tunicamycin induced expression of CHOP (Fig. 10). These results are consistent with the possibility that taurine exerts hepatoprotective effect in NAFLD at least in part by reducing ER stress.

**DISCUSSION**

Taurine is a small amino sulfonic acid that can be obtained through the diet or synthesized endogenously from methionine and cysteine (12). Taurine aids in numerous physiological processes, including bile salt formation, osmoregulation, central nervous system function, and calcium homeostasis (19). Epidemiological data demonstrate that dietary taurine intake is inversely related to the prevalence of metabolic diseases, and clinical and experimental studies suggest that taurine supplementation protects against metabolic disturbances, including diabetes and its complications (12, 56). Furthermore, taurine supplementation is protective against various hepatic insults, such as those imposed by cyclosporine-A, acetaminophen, a high-methionine diet, and alcohol (7, 11, 16, 70, 75). In the present study, we extend these findings by demonstrating that taurine reduces nutrient (palmitate, high-sucrose diet)- and chemical (tunicamycin)-induced hepatic steatosis, ER stress, inflammation, and injury. Importantly, the beneficial effects of taurine were consistent across four models: palmitate incubation of isolated primary hepatocytes and H4IIE liver cells, long-term (4-wk) high-sucrose feeding in rats, and acute tunicamycin injection in mice, indicating that dietary taurine supplementation has considerable potential as a preventative strategy in diet-induced NAFLD.

The mechanisms by which taurine exerts its beneficial effects are unknown, although several possibilities exist. For example, substantial evidence indicates that taurine protects a wide variety of cells from oxidative damage by increasing antioxidant defense systems (40, 66), decreasing the formation

---

**Fig. 9.** Effects of taurine in mice injected with tunicamycin. Liver weight (A); H&E stain and liver triglycerides (B); ALT (C). Con, control and carrier injected; Con + T, carrier injected and provided taurine in drinking water; Tun, tunicamycin injected; Tun + T, tunicamycin injected and provided taurine in drinking water. Values are means ± SD for n = 6/group. *Significantly different from all other groups.
Fig. 10. Effects of taurine on ER stress in mice injected with tunicamycin. Immunostaining for KDEL (a tetrapeptide located at the COOH-terminal sequence of luminal proteins) (A) and C/EBP homologous protein (CHOP) (B) in liver tissue. Groups are described in Fig. 9. Scale bar = 200 μm.
of reactive oxygen species (28, 56), and interfering with reactive oxygen species activity (18, 37). In the present study, taurine reduced 1) palmitate-mediated protein carbonyl formation in H4IIE liver cells, which is elevated in patients suffering from NAFLD or type 2 diabetes (9, 34, 62); 2) palmitate-mediated DCF fluorescence in H4IIE liver cells and primary hepatocytes; and 3) reduced plasma TBARS in high-sucrose diet-fed rats. Collectively these results suggest that taurine, directly or indirectly, can mitigate oxidative stress in the liver.

The ER provides a unique oxidizing environment for protein folding and disulfide bond formation. Each disulfide bond formed during oxidative protein folding produces a single reactive oxygen species. It has been estimated that secretory cells produce 3–6 million disulfide bonds per minute; thus it has been postulated that protein folding in the ER is intimately linked to oxidative stress (33, 55, 58). Indeed, oxidants not only provoke ER stress but also are signals generated by misfolded proteins in the ER that then activate the UPR and can lead to cell death (33, 55, 58).

In the present study, taurine reduced or prevented palmitate-, sucrose-, and tunicamycin-mediated ER stress and UPR activation. These results are in line with recent reports indicating that taurine mitigates ER stress in lung tissue and vascular cells following various insults (36, 40, 80) and suggest that attenuation of ER stress may be an important mechanism by which taurine leads to reduced inflammation, liver injury, and cell death. These data raise the possibility that, in environments conducive to the generation of either stress (e.g., obesity), a self-perpetuating cycle of ER stress and oxidative stress may hasten the development and progression of NAFLD and culminate, over time, in steatohepatitis and/or end-stage liver disease. Results from the current experiments suggest that taurine may break this cycle and prevent long-term liver damage.

In the present study, taurine reduced or prevented hepatic steatosis in high-sucrose diet-fed rats and in mice injected with tunicamycin. High-sucrose diets produce hepatic steatosis primarily through lipogenesis, whereas tunicamycin-mediated steatosis appears to result from impairments in the expression of genes involved in fatty acid oxidation and is augmented by reduced lipoprotein secretion. Recent studies have linked the UPR to the control of lipid biosynthesis, fatty acid oxidation, and lipoprotein secretion (27, 42, 54); therefore we speculate that the improvement in steatosis mediated by taurine is the result of reduced ER stress and UPR activation.

Chronic ER stress and activation of the UPR has been linked to impairments in insulin action, activation of inflammatory cascades and the innate immune response, and apoptosis (21, 31, 44). Thus, it is attractive to suggest that the ability of taurine to reduce palmitate-mediated cell death, inflammation, and liver injury results from a centralized effect on ER homeostasis. However, a few observations from the present study suggest that the effects of taurine may be more complex. First, in liver cells, taurine reduced ER stress markers at both concentrations of palmitate, but significant reductions in caspase-3 activity and cell death were only observed at high concentrations of palmitate. Thus, chronic ER stress and UPR activation are clearly not the only mediators of palmitate-mediated cell death. Second, taurine did not reduce palmitate-mediated Xbp1 splicing. Although this may be due to the inability to detect small changes in Xbp1 splicing, it suggests that the IRE1 branch of the UPR may remain active in the presence of taurine. The ability to maintain activation of this branch of the UPR has been linked to cell survival (29); thus the maintenance of Xbp1 splicing in cells may be linked to reduced cell death.

Obesity and NAFLD are largely diseases of volition, and despite worldwide public-health campaigns recommending lifestyle and dietary changes, many people are not following these recommendations. It is conceivable that taurine could be used in food/drink fortification strategies in a manner analogous to that of folic acid supplementation of flour. This approach, by acting as a passive therapy has lead to dramatic decreases (up to 78% in some populations) in the incidence of neural tube defects (74). In this context, taurine has a number of advantages as a potential preventative treatment for NAFLD in that it is inexpensive, nontoxic, and can be administered orally. However, there are some limitations of the present study that should be noted. In regards to DCF fluorescence as a marker of oxidative damage, we cannot rule out the possibility that reactive species that do not react with DCFH may remain operative in the presence of taurine, and therefore we have underestimated the contribution of oxidative stress to palmitate-mediated cell damage and death. Also, the use of this probe to estimate oxidative stress during apoptosis should be approached with caution, as cytochrome c is a powerful catalyst of DCFH oxidation (17). Finally, although the results of the current experiments suggest that the beneficial effects of taurine are accompanied by reductions in oxidative stress and ER stress, the methods employed cannot determine causality, nor can they delineate the respective contribution of each stress. In summary, by utilizing four models of liver damage, our results indicate that taurine is protective against nutrient- and ER stress-induced hepatic steatosis and liver injury. These data suggest that taurine has significant potential as a preventative and therapeutic treatment in NAFLD.

GRANTS

Financial support for this study was from National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-072017 and DK-47416, and the Lillian Fountain Smith Endowment (to M. J. Pagliassotti) and National Institute of Diabetes and Digestive and Kidney Diseases DK-074487 (to D. R. Petersen). C. L. Gentile was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants 1F32-DK-082166 and 1K01-DK-087777.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS


REFERENCES